OliX PharmaceuticalsInc (226950) - Net Assets

Latest as of September 2025: ₩142.56 Billion KRW ≈ $96.61 Million USD

Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has net assets worth ₩142.56 Billion KRW (≈ $96.61 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩186.58 Billion ≈ $126.44 Million USD) and total liabilities (₩44.02 Billion ≈ $29.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OliX PharmaceuticalsInc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩142.56 Billion
% of Total Assets	76.41%
Annual Growth Rate	4.49%
5-Year Change	-60.59%
10-Year Change	N/A
Growth Volatility	111.96

OliX PharmaceuticalsInc - Net Assets Trend (2016–2024)

This chart illustrates how OliX PharmaceuticalsInc's net assets have evolved over time, based on quarterly financial data. Also explore 226950 total asset value for the complete picture of this company's asset base.

Annual Net Assets for OliX PharmaceuticalsInc (2016–2024)

The table below shows the annual net assets of OliX PharmaceuticalsInc from 2016 to 2024. For live valuation and market cap data, see OliX PharmaceuticalsInc market capitalisation.

Year	Net Assets	Change
2024-12-31	₩17.85 Billion ≈ $12.10 Million	-64.54%
2023-12-31	₩50.34 Billion ≈ $34.11 Million	-23.63%
2022-12-31	₩65.91 Billion ≈ $44.66 Million	+255.85%
2021-12-31	₩18.52 Billion ≈ $12.55 Million	-59.10%
2020-12-31	₩45.29 Billion ≈ $30.69 Million	+8.34%
2019-12-31	₩41.80 Billion ≈ $28.33 Million	-23.92%
2018-12-31	₩54.94 Billion ≈ $37.23 Million	+194.16%
2017-12-31	₩18.68 Billion ≈ $12.66 Million	+48.73%
2016-12-31	₩12.56 Billion ≈ $8.51 Million	--

Equity Component Analysis

This analysis shows how different components contribute to OliX PharmaceuticalsInc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 15561449651000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	₩9.23 Billion	51.71%
Other Components	₩171.39 Billion	960.20%
Total Equity	₩17.85 Billion	100.00%

OliX PharmaceuticalsInc Competitors by Market Cap

The table below lists competitors of OliX PharmaceuticalsInc ranked by their market capitalization.

Company	Market Cap
Ningbo Boway Alloy Material Co Ltd SHG:601137	$2.35 Billion
Immunome Inc NASDAQ:IMNM	$2.35 Billion
Terna Energy Societe Anonyme Commercial Technical Company AT:TENERGY	$2.35 Billion
Ardagh Metal Packaging SA NYSE:AMBP	$2.35 Billion
Washington Federal Inc NASDAQ:WAFD	$2.35 Billion
Easyhome New Retail Group Co Ltd SHE:000785	$2.35 Billion
Krungthai Card PCL BK:KTC	$2.35 Billion
Zhejiang Shenghua Biok Biology Co Ltd SHG:600226	$2.35 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in OliX PharmaceuticalsInc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 49,854,507,610 to 17,848,889,860, a change of -32,005,617,750 (-64.2%).
Net loss of 40,658,699,600 reduced equity.
Other factors increased equity by 8,653,081,850.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-40.66 Billion	-227.79%
Other Changes	₩8.65 Billion	+48.48%
Total Change	₩-	-64.20%

Book Value vs Market Value Analysis

This analysis compares OliX PharmaceuticalsInc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 178.40x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 124.35x to 178.40x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩1387.16	₩172500.00	x
2017-12-31	₩1793.90	₩172500.00	x
2018-12-31	₩4223.45	₩172500.00	x
2019-12-31	₩3200.42	₩172500.00	x
2020-12-31	₩3344.07	₩172500.00	x
2021-12-31	₩1351.59	₩172500.00	x
2022-12-31	₩4809.65	₩172500.00	x
2023-12-31	₩3114.01	₩172500.00	x
2024-12-31	₩966.92	₩172500.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently OliX PharmaceuticalsInc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -227.79%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -716.18%
• Asset Turnover: 0.08x
• Equity Multiplier: 3.99x
Recent ROE (-227.79%) is below the historical average (-67.12%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	-29.11%	-932.79%	0.03x	1.21x	₩-4.91 Billion
2017	-27.65%	-2116.65%	0.01x	1.16x	₩-7.03 Billion
2018	-14.09%	-2563.58%	0.01x	1.01x	₩-13.24 Billion
2019	-34.34%	-1269.79%	0.03x	1.08x	₩-18.53 Billion
2020	-42.81%	-783.44%	0.03x	1.74x	₩-23.91 Billion
2021	-160.44%	-808.70%	0.04x	4.68x	₩-31.57 Billion
2022	-29.58%	-209.17%	0.07x	2.01x	₩-26.09 Billion
2023	-38.31%	-111.94%	0.17x	2.06x	₩-24.09 Billion
2024	-227.79%	-716.18%	0.08x	3.99x	₩-42.44 Billion

Industry Comparison

This section compares OliX PharmaceuticalsInc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $210,358,050,483
Average return on equity (ROE) among peers: 4.01%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
OliX PharmaceuticalsInc (226950)	₩142.56 Billion	-29.11%	0.31x	$2.35 Billion
ORIENTBIO Inc. (002630)	$85.10 Billion	15.13%	0.14x	$43.15 Million
Green Cross (005250)	$221.73 Billion	2.76%	8.07x	$425.10 Million
Green Cross Holdings Preference Shares (005257)	$1.44 Trillion	3.01%	0.78x	$3.74 Million
Pharmicell (005690)	$76.66 Billion	10.78%	0.43x	$736.42 Million
GeneOne Life Science Inc (011000)	$26.74 Billion	0.00%	0.49x	$49.94 Million
HLB Co. Ltd (028300)	$46.46 Billion	0.00%	0.75x	$5.41 Billion
Daesung Microbiological Labs. Co. Ltd (036480)	$30.30 Billion	5.14%	0.15x	$19.29 Million
Seoulin Bioscience Co.Ltd (038070)	$53.72 Billion	4.89%	0.32x	$37.92 Million
Hyundai Bioscience Co. Ltd (048410)	$58.24 Billion	3.27%	0.77x	$872.13 Million
iNtRON Biotechnology Inc (048530)	$64.96 Billion	-4.91%	0.37x	$77.34 Million

About OliX PharmaceuticalsInc

KQ:226950 Korea Biotechnology

Market Cap

$2.35 Billion

₩3.47 Trillion KRW

Market Cap Rank

#5669 Global

#145 in Korea

Share Price

₩172500.00

Change (1 day)

-6.55%

52-Week Range

₩34800.00 - ₩207000.00

All Time High

₩207000.00